Bard Gets Fed. Circ. To Revive $68M Infringement Trial
By Dani Kass (November 10, 2020, 10:55 PM EST) -- A Delaware federal judge made several mistakes when he stopped an infringement trial with $67.5 million on the line to conclude medical device maker C.R. Bard's patent claims were invalid and not infringed by AngioDynamics, the Federal Circuit said Tuesday.
A three-judge panel said the patents directed to identifying vascular access ports hold up under Section 101 of the Patent Act — despite U.S. District Judge Joseph F. Bataillon's finding otherwise — and that Bard deserves to finish the jury trial.
"Because there remained triable issues of fact as to the infringement and validity of the asserted claims, the district court...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!